Biotech startup Pandorum Technologies is set to raise ₹85 crore (~US$10 million) in a Series B funding round led by Protons Corporate. The fresh capital aims to enhance Pandorum’s tissue-engineering platform, expand operations, and support subsidiaries as the company moves toward clinical and commercial applications of lab-grown human tissues.
Glimpse:
Under the funding round, Pandorum’s board approved issuance of 35,326 Series B preference shares at ₹23,920 each. Protons Corporate is reportedly investing around ₹27 crore, while other investors including angel backers contribute to the remainder. The first tranche of around ₹45 crore has already been received, with the rest expected soon. This boost comes as Pandorum scales up its regenerative-medicine research and readies production for human-tissue models for drug testing and therapeutics.
Founded in 2011 by researchers from a top science institution, Pandorum Technologies specialises in tissue engineering and regenerative medicine, creating lab-grown human tissues such as bio-printed liver models and engineered corneas. Over the years, the company has built an impressive track record becoming the first Indian firm to 3D-print human liver tissue for research and later progressing to corneal tissue engineering.
In its recent Series B funding round, Pandorum will issue 35,326 preference shares at a stated price, raising ₹85 crore overall. Protons Corporate, part of the Karbhari Group, leads with ₹27 crore, while other institutional and angel investors (including some names from earlier rounds) are also participating. The funds will help the company expand manufacturing and R&D capacity, bolster subsidiaries, and possibly accelerate clinical- and regulatory-pathway preparations for its regenerative and tissue-model products.
Prior to this, in March 2024, Pandorum had secured US$ 11 million (~₹88 crore) in a pre-Series B round aimed at advancing its flagship product a bio-engineered “liquid cornea” (branded “Kuragenx”) toward first-in-human trials. The new funding builds on that momentum and signals investor confidence in the company’s deep-tech approach and long-term vision of reducing dependence on donor tissues for transplants, offering a potential path to organ/tissue scarcity solutions.
“With this new capital, we are doubling down on our vision bringing lab-grown human tissues from the bench to bedside and redefining what’s possible in regenerative medicine.”
By
HB Team
